Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

Anja Kafka, Davor Tomas, Mirna Lechpammer, Tea Gabud, Leo Pažanin, Nives Pećina-Šlaus

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The expression patterns of critical molecular components of Wnt signaling, sFRP3 and DVL3, were investigated in glioblastoma, the most aggressive form of primary brain tumors, with the aim to offer potential biomarkers. The protein expression levels and localizations in tumor tissue were revealed by immunohistochemistry and evaluated by the semiquantitative method and immunoreactivity score. Majority of glioblastomas had moderate expression levels for both DVL3 (52.4%) and sFRP3 (52.3%). Strong expression levels were observed in 23.1% and 36.0% of samples, respectively. DVL3 was localized in cytoplasm in 97% of glioblastomas, of which 44% coexpressed the protein in the nucleus. sFRP3 subcellular distribution showed that it was localized in the cytoplasm in 94% of cases. Colocalization in the cytoplasm and nucleus was observed in 50% of samples. Wilcox test indicated that the domination of the strong signal is in connection with simultaneous localization of DVL3 protein in the cytoplasm and the nucleus. Patients with strong expression of DVL3 will significantly more often have the protein in the nucleus (P=6.33×10-5). No significant correlation between the two proteins was established, nor were their signal strengths correlated with epidemiological parameters. Our study contributes to better understanding of glioblastoma molecular profile.

Original languageEnglish (US)
Article number9253495
JournalDisease Markers
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma'. Together they form a unique fingerprint.

Cite this